The management of Helicobacter pylori infection in primary care: a systematic review of the literature.
OBJECTIVE
The aim of the present study was to provide evidence from the literature to inform the production of guidelines by the European Society for Primary Care Gastroenterology (ESPCG) for the management of Helicobacter pylori infection in primary care.


METHODS
A systematic review was conducted, searching MEDLINE, EMBASE and the Cochrane Library. The systematic review was designed to answer a number of question: the role of H.pylori in the aetiology of peptic ulcer disease (PUD), gastric cancer (GC), non-ulcer dyspepsia (NUD) and oesophagitis; non-invasive testing for H.pylori and post-treatment testing; eradication therapy; and cost issues. Selection of records concentrated on the highest quality studies, i.e. systematic reviews, meta-analyses and cost analyses.


RESULTS
Helicobacter pylori infection is a causal factor in PUD and GC but not in NUD or oesophagitis. Serological tests and urea breath tests (UBTs) can be used for the detection of H.pylori, but UBT is the preferred choice for post-treatment testing. Proton pump inhibitor (PPI)-based triple regimens are the preferred eradication therapy. Eradication therapy is more cost-effective than long-term maintenance therapy.


CONCLUSIONS
Strong evidence is available for answering questions on the aetiology of stomach ulcers and GU, eradication therapies and cost issues. Weaker evidence is available for answering the questions on the aetiology of NUD and non-invasive testing. No evidence is available for answering the question on the role of H.pylori in the aetiology of oesophagitis.
Childs
S
S
Centre for Health Studies, University of Durham, 32 Old Elvet, Durham DH1 3HN, UK.
Roberts
A
A
Meineche-Schmidt
V
V
de Wit
N
N
Rubin
G
G
D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004415:Dyspepsia / Q000382:microbiology*; D004941:Esophagitis / Q000382:microbiology*; D019317:Evidence-Based Medicine; D016481:Helicobacter Infections / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans; D010437:Peptic Ulcer / Q000382:microbiology*; D017410:Practice Guidelines as Topic; D011320:Primary Health Care / Q000191:economics / Q000379:methods*; D054328:Proton Pump Inhibitors; D012107:Research Design; D013274:Stomach Neoplasms / Q000382:microbiology*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors